Voydeya destina-se a doentes que continuam a sofrer de EVH apesar do tratamento com inibidores C5
A Alexion/AstraZeneca Rare Disease recebeu aprovação da Food and Drug Administration (FDA) dos EUA para Voydeya (danicopan) como uma terapia comple
Alexion (2)
Alexion (NASDAQ: ALXN) is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing therapies.
Since its founding in 1992, Alex
